Clinical trial of CV. artecan (dihydroartemisinin-piperaquine) combination against malaria in Viet nam
- Author:
Doan Hanh Nhan
- Publication Type:Journal Article
- Keywords:
malaria, combination treatment
- MeSH:
malaria;
therapeutics;
therapy;
Artemisinins;
Quinolines
- From:Journal of Malaria and parasite diseases Control
2003;0(4):20-26
- CountryViet Nam
- Language:Vietnamese
-
Abstract:
The evaluation of the safety and therapeuctic efficacy of CV.artecan (dihydroartemisinin 40mg - piperaquine 320mg) combination in experimental mice. LD50 dose of CV.artecan were identified in experimental mice. In vitro test was carried out on mice injected P.berghei (chloroquine resistant isolate) treated with various doses of CV.artecan: 115.2mg/kg; 230.4mg/kg; 460.8mg/kg and 921.6mg/kg. In vivo tests of CV.artecan with the total doses of 6.2/51.2mg/kg in 137 patients with uncomplicated malaria.Therapeutic dose of adults in the first day: 4 tablets divided into 2 times, the first day and second day: 2 tablets per day, the children doses acorrding to age. The patients were followed up for 28 days. The results: The dose LD50 of CV.artecan was identified as 2167mg/kg (2129-2205mg/kg). The total dose of CV.artecan 57mg/kg in malaria patients was far duration from LD50 doses
